Resveratrol Attenuates CSF Markers of Neurodegeneration and Neuroinflammation in Individuals with Alzheimer’s Disease
International Journal of Molecular Sciences · 23.05.2025 · 26 (11) · 5044
DOI: 10.3390/ijms26115044 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.05.2025. Verfasst von Xiaoguang Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Dementia and Parkinsonism, Translational Neurotherapeutics Program, Department of Neurology, Georgetown University Medical Center, Was…. Hauptthemen laut MEDLINE: Alzheimer Disease, Biomarkers, Neuroinflammatory Diseases, Resveratrol. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, Georgetown University.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that is characterized by amyloid-beta (Aβ) accumulation and neuroinflammation. A previous multicenter, phase 2, double-blind, placebo-controlled trial randomized 179 participants into placebo or resveratrol over 52 weeks. Sub-analysis of CSF biomarkers of neuronal damage, inflammation, and microglial activity was performed in a subset of patients treated with a placebo (n = 21) versus resveratrol (n = 30). Markers of neuronal damage, including neuron-specific enolase and hyperphosphorylated neurofilaments, were reduced. Microglial activation was measured via a triggering receptor expressed on myeloid cells (TREM)-2 at baseline and after resveratrol treatment. Resveratrol significantly reduced CSF TREM2 levels and decreased inflammation and tissue damage, including matrix metalloprotease (MMP)-9. Cathepsin D, a lysosomal marker of autophagy, was reduced in the resveratrol group compared with placebo, while angiogenin, a marker of vascular angiogenesis, was increased. These data suggest that resveratrol may exert anti-inflammatory and neuroprotective effects in AD by reducing CSF TREM2 and other markers of neuronal damage. Further research is needed to assess the significance of these biomarker changes on clinical outcomes in patients with neurodegenerative diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory for Dementia and Parkinsonism, Translational Neurotherapeutics Program, Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA.
- Interdisciplinary Program in Neuroscience, Georgetown University Medical Center, Washington, DC 20057, USA.
- Memory Disorders Program, Department of Neurology, Georgetown University, Washington, DC 20057, USA.
ORCID-Profile: Sean Baxley, Raymond Scott Turner, Charbel Moussa
Förderung
- NIGMS NIH HHS
- Georgetown University
Zitieren
APA
Liu, X., Baxley, S., Hebron, M., Turner, R. S., & Moussa, C. (2025). Resveratrol Attenuates CSF Markers of Neurodegeneration and Neuroinflammation in Individuals with Alzheimer’s Disease. International Journal of Molecular Sciences, 26(11), 5044. https://doi.org/10.3390/ijms26115044
Vancouver
Liu X, Baxley S, Hebron M, Turner RS, Moussa C. Resveratrol Attenuates CSF Markers of Neurodegeneration and Neuroinflammation in Individuals with Alzheimer’s Disease. International Journal of Molecular Sciences. 2025;26(11):5044. doi:10.3390/ijms26115044
BibTeX
@article{Liu2025,
author = {Liu, Xiaoguang and Baxley, Sean and Hebron, Michaeline and Turner, Raymond Scott and Moussa, Charbel},
title = {Resveratrol Attenuates CSF Markers of Neurodegeneration and Neuroinflammation in Individuals with Alzheimer’s Disease},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {11},
pages = {5044},
doi = {10.3390/ijms26115044}
}
EUVIMED